OncoMatch/Ovarian Cancer/Folate Receptor Alpha (FRα)
Ovarian CancerFolate Receptor Alpha (FRα) Clinical Trials
Folate receptor alpha (FRα, encoded by FOLR1) is overexpressed in the large majority of high-grade serous ovarian carcinomas and is an established therapeutic target. Mirvetuximab soravtansine, a FRα-directed ADC, received FDA accelerated approval for FRα-positive (IHC 2+ or 3+) platinum-resistant ovarian/fallopian tube/primary peritoneal cancer after 1–3 prior regimens (SORAYA trial), and subsequently full approval based on MIRASOL. Trials investigate mirvetuximab in earlier lines, combinations with bevacizumab or IO agents, and next-generation FRα-directed ADCs.
Top recruiting Folate Receptor Alpha (FRα) Ovarian Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
AbbVie
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
AbbVie
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
University of Alabama at Birmingham
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
AbbVie
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver